Previous participation in a FCM trial

Known hypersensitivity reaction to FCM or iron dextran

Requires dialysis for treatment of chronic kidney disease

Current anemia not attributed to iron deficiency

Received IV iron, RBC transfusion(s), or antibiotics 10 days prior and during the screening phase

Anticipated need for surgery during the 30 day period prior to screening or during the study period

AST or ALT greater than 1.5 times the upper limit of normal

Received an investigational drug within 30 days of screening

Women who are breastfeeding

Pregnant or sexually-active females who are not willing to use an effective form of birth control

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia